Pharma: Page
-
Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 125 million doses of Pfizer and BioNTech's vaccine for supply in Europe.
By Ned Pagliarulo • Updated Jan. 27, 2021 -
Jacob Bell/BioPharma Dive
AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica
A head-to-head study showed Calquence and Imbruvica benefited patients similarly, but AstraZeneca's drug had fewer heart-related side effects.
By Jonathan Gardner • Jan. 25, 2021 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Shutterstock.com/totojang1977
Sponsored by Medidata, a Dassault Systèmes companyCOVID-19 study builds at pandemic speed
How to accelerate time-to-market, gain greater control of study data and execution, and optimize the entire trial lifecycle.
Jan. 25, 2021 -
Long-acting HIV drug secures FDA approval, giving GSK a competitive boost
Rather than a once-a-day pill, Cabenuva comes as a once-a-month injection. That convenience could become a valuable tool for GSK as it tries to broaden adoption of two-drug treatments.
By Jacob Bell • Jan. 22, 2021 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
Pfizer, BioNTech say vaccine effective against fast-spreading UK coronavirus variant
BioNTech's CEO has also promised data will soon be available on the shot's protection against a South African variant that's worried public health experts.
By Jonathan Gardner • Jan. 20, 2021 -
Merck, Bayer win FDA approval for heart failure drug
The drugmakers could face an uphill battle, however, to market the medicine, which showed a more modest benefit than expected in a key study.
By Kristin Jensen • Jan. 20, 2021 -
Kendall Davis/Industry Dive/BioPharma Dive, data from Marc Nozell
Former FDA chief Kessler tapped as top Biden adviser for COVID-19 response
David Kessler, who served in both the first Bush and Clinton administrations, will be joined by former acting Medicare head Andy Slavitt in a revamped effort from the new administration.
By Jonathan Gardner • Jan. 15, 2021 -
Permission granted by PQE Group
Sponsored by PQE GroupPQE Group creates an internal research task force to fight the spread of misinformation in relation to COVID-19
PQE Group creates internal task force to fight the biggest side effect of the Covid-19 pandemic: the infodemic. A common vocabulary to reinforce knowledge, security and safety.
Jan. 11, 2021 -
Permission granted by Roche
Roche adds to RNA drug deal streak with Ribometrix partnership
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.
By Ben Fidler • Jan. 6, 2021 -
AbbVie, Biogen lead pharma in new year's drug price hikes
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis.
By Jonathan Gardner • Jan. 4, 2021 -
Permission granted by Bristol-Myers Squibb
How an all-or-nothing bet on 3 Bristol Myers drugs came undone
With no decision from the FDA on approval of an experimental cancer cell therapy, an agreement by Bristol Myers to pay out more money as part of its Celgene acquisition fell apart.
By Ned Pagliarulo • Jan. 4, 2021 -
Getty Images
Sponsored by SGSSurface plasmon resonance in biopharmaceutical industry: Real-time and label-free characterization
Surface Plasmon Resonance (SPR) is a robust, but complex analytical tool that provides paramount value to the development and understanding biopharmaceutical products.
By Dr. Sasmit S. Deshmukh and Dr. Alex Perieteanu • Jan. 4, 2021 -
Courtesy of AstraZeneca
UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger
The first public vaccinations with AstraZeneca and Oxford’s shot are now underway. But it’s still unclear how effective the vaccine is, or the best way to use it.
By Ben Fidler • Dec. 30, 2020 -
Merck signs $356M deal to supply US with experimental coronavirus drug
The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.
By Jonathan Gardner • Dec. 23, 2020 -
Courtesy of BioNTech
US pays another $2B to buy more doses of Pfizer, BioNTech coronavirus vaccine
The new deal will provide the U.S. with 100 million additional doses of Pfizer and BioNTech's shot, but the much-needed supply won't be available for several months.
By Ben Fidler • Dec. 23, 2020 -
Permission granted by University of Maryland School of Medicine
Rollout of Pfizer's coronavirus vaccine hits some speed bumps amid confusion over shipments
Several thousand doses were returned and replaced after getting too cold. Pfizer and the federal government, meanwhile, don't appear to be on the same page for the next wave of shipments.
By Matt Leonard • Dec. 18, 2020 -
Novartis acquires a small biotech and its trio of brain drugs
More active in neuroscience than most pharmaceutical firms, Novartis would gain three experimental drugs for depression, schizophrenia and movement disorders through the deal.
By Jacob Bell • Dec. 17, 2020 -
With trial plans, Novo wagers its diabetes drug can help treat Alzheimer's
Similar diabetes drugs from Novo have shown signs of promise in treating dementia. The Danish biotech is now putting that hypothesis to the test.
By Jonathan Gardner • Dec. 16, 2020 -
Courtesy of BioNTech
In historic decision, FDA clears coronavirus vaccine from Pfizer, BioNTech
The vaccine was the first authorized for emergency use in the U.S. after a large study showed it to be highly protective against COVID-19, a landmark moment amid a worsening pandemic.
By Jonathan Gardner • Dec. 11, 2020 -
Viatris to lay off staff, shutter plants in major restructuring
The company created by a merger of Mylan and Pfizer's Upjohn unit is dramatically cutting costs, shedding jobs and closing or divesting up to 15 plants worldwide.
By Ned Pagliarulo • Dec. 11, 2020 -
Sanofi, GSK coronavirus vaccine delayed after early study disappoints
The experimental shot produced a weak immune response in adults over 49, leading the partner drugmakers to change plans and push back their development timelines.
By Ben Fidler • Dec. 11, 2020 -
Boehringer goes after antibody cancer drugs in latest acquisition
For about $1.4 billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy.
By Kristin Jensen • Dec. 10, 2020 -
Jonathan Gardner/BioPharma Dive
Lilly to pit Loxo cancer drug against top-selling rival after strong study results
Following positive data at ASH, Lilly will test a drug it acquired in last year's buyout of Loxo Oncology against Imbruvica, one of the world's best-selling cancer treatments.
By Ned Pagliarulo • Dec. 7, 2020 -
Sponsored by SAP
Solving supply chain volatility
Supply chain management technologies help monitor shifting demand patterns and ensure life-saving medications reach people quickly and at manageable costs.
By Mandar Paralkar, Global Head of Life Sciences at SAP • Dec. 7, 2020 -
J&J study finds multiple myeloma cell therapy to be strongly effective
Safety issues that have dogged the CAR-T field remain, however, with the drugmaker reporting some severe side effects, including several that led to patient deaths.
By Jonathan Gardner • Dec. 5, 2020
Previous
